Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Continued single digit volume growth within the insulin segments globally Slide 30 Fast-acting insulin Segment volume NovoRapidⓇ market share Premix insulin Segment volume NovoMix® market share Long-acting insulin Segment volume TresibaⓇ share - LevemirⓇ share tMU 100% CAGR¹ volume: 4.9% 200 MI penetration: 77.9% tMU 200 CAGR¹ volume: 1.5% MI penetration: 46.4% 100% tMU CAGR¹ volume: 5.8% 100% 200 MI penetration2: 82.5% - 80% 80% 80% 160 160 160 - 60% 60% 60% 120 120 120 +40% 40% 80 40% 80 80 40 + 20% 40 20% 40 20% 0% 0% 0 0% Nov 2012 Nov 2017 Nov 2012 Nov 2017 Nov Nov 2012 2017 1 CAGR for 5-year period. 2 Includes new-generation Insulin. tMU: Thousand mega units Note: Modern insulin (MI) penetration is of total segment, ie including animal and human insulin; Data is sensitive to changes in IQVIA data collection and reporting methodology Source: IQVIA (formerly IMS) MAT Nov, 2017 volume figures changing diabetes novo nordisk

View entire presentation